Our lead program focuses on FORE8394, an investigational drug identified by our platform for its ability to inhibit a wide range of untreated mutations in cancer cells that have historically been overlooked.
Building our pipeline
The Foresight platform enables a repeatable approach to building the pipeline. Our approach is to identify and in-license new clinic-ready assets that have the potential to serve as precision treatments for unaddressed patient populations.
We focus primarily on compounds that have passed Phase 1 trials and are proven to be safe, for which the main challenge is pinpointing which patient populations they will benefit most. We also consider pre-IND compounds where the biology is well understood and clinical trials are within sight.
We accommodate a wide range of partnering structures, with a focus on in-licensing compounds. To discuss a potential collaboration, please contact our business development team at: oib.e1680393299rof@r1680393299entra1680393299p1680393299.